A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours

@article{Wachters2004API,
  title={A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours},
  author={Floris M. Wachters and Harry J. M. Groen and Jan Gerard Maring and Jourik A. Gietema and Maria Grazia Porro and Herlinde Dumez and Elisabeth G. E. de Vries and Allan T. van Oosterom},
  journal={British Journal of Cancer},
  year={2004},
  volume={90},
  pages={2261 - 2267}
}
In MAG-camptothecin (MAG-CPT), the topoisomerase inhibitor camptothecin is linked to a water-soluble polymer. Preclinical experiments showed enhanced antitumour efficacy and limited toxicity compared to camptothecin alone. Prior phase I trials guided the regimen used in this study. The objectives were to determine the maximum tolerated dose, dose-limiting toxicities, safety profile, and pharmacokinetics of weekly MAG-CPT. Patients with solid tumours received MAG-CPT intravenously administered… CONTINUE READING